NattoPharma Signs Agreement with Nutriangels, Expands MenaQ7 Brazil Presence
16 Jun 2017 --- NattoPharma has announced a new partnership with Nutriangels, a Brazilian nutraceutical brand with products that include chelated minerals, further expanding the presence of MenaQ7 Vitamin K2 as MK-7 in Brazil. The company reports that Nutriangels launched K2 + featuring MenaQ7 in Q2 2017, adding that the product has already been well received. K2 + is positioned to support both bone and cardiovascular health.
“Brazil is a burgeoning market where NattoPharma already enjoys an established presence. Nutriangels is one of the new pioneering supplement brands serving Brazil and we are thrilled to see this new customer expand our MenaQ7 offering with consumer-targeted, science-based products,” says Eric Anderson, Senior Vice President of Global Sales and Marketing with NattoPharma.
“This milestone marks a welcome increase in awareness of the importance of Vitamin K2 for human health, and the global recognition that MenaQ7 is the clinically validated branded Vitamin K2 as MK-7 of choice,” Anderson says.
Earlier this week, NattoPharma highlighted the results of a study on the link between low vitamin K2 status and increased risk of fracture in children.
“NattoPharma's clinical trials with adult and child populations have shown that children have the greatest need for vitamin K2, as their bones are growing and developing so intensely, and [the trials have] confirmed that just 45mcg daily of MenaQ7 Vitamin K2 had a profound impact on children's bone health,” Kate Quackenbush, NattoPharma’s Director of Communications, told NutritionInsight.
Regarding the application opportunities for K2, Quackenbush says the company’s “ultimate goal is to see MenaQ7 Vitamin K2 as MK-7 as a core nutrient in all multivitamins, but in particular for kids and prenatal multis that provide a sound foundation for health as early as possible.”
“From a claims perspective, in Europe, due to EFSA regulations, health claims must be applied for and awarded. We are hopeful that this will occur in the coming years. However, given EFSA's recent performance, this is yet to be seen,” she adds.
“In other parts of the world, the regulatory guidelines are different. Regardless, one must have scientific substantiation in the body of evidence that validates the claim. NattoPharma has extensive research including in vitro, in vivo and 16 published human studies (with more underway), that clearly demonstrate the mechanism of vitamin K2 and the subsequent real health benefits such as preserving bone health and mass, and preserving arterial flexibility,” Quackenbush states.
